Dermatológia pre prax 1/2022
Current pharmacotherapy of hidradenitis suppurativa
Hidradenitis suppurativa (HS) is chronic, immunology-mediated inflammatory disease with important impact on quality of life. Important pharmacotherapeutic progress reflect new knowledges in etiopathogenesis of the disease. Currently, besides traditional remedies, the pharmacological portfolio supplement the biologics. Paper summarize current on-labe and off-label pharmacological approaches in the treatment of this serious disease.
Keywords: hidradenitis suppurativa, guideleines, clindamycin, doxycycline, adalimumab, secukinumab
